Vaccine-Chemo Combo Alters Tumors in Pancreatic Cancer
the MPR take:
The results of a trial published in the journal Cancer Immunology Research are extremely promising for the efficacy of a vaccine-chemotherapy combination in converting pancreatic ductal adenocarcinomas (PDAC) into immunogenic cancers that could respond to immunotherapy. Thirty-nine patents with resectable PDAC were randomized to receive irradiated, granulocyte-macrophage colony-stimulating factor–secreting, allogeneic vaccine (GVAX), GVAX vaccine alone, GVAX with one 200mg/m2 dose of intravenous cyclophosphamide one day before vaccine, or GVAX with 100mg once daily oral cyclophosphamide for one week on and one week off. All patients underwent tumor resection surgery two weeks post-vaccination. Tumors from 84.6% of the patients had developed vaccine-induced intratumoral tertiary lymphoid aggregates, indicating immunogenicity. In addition, lymphoid aggregates in tumors from patients who survived >3 years post-vaccine therapy had significantly greater IL17A protein expression vs. patients who survived <1.5 years post-vaccination (P=.02). This, the researchers note, may be why vaccination and immune modulation as single-agent therapies was not effective in patients with PDAC in previous studies.
According to a study highlighted in GI & Hepatology News, a therapeutic vaccine combined with low-dose chemotherapy converted pancreatic ductal adenocarcinomas into immunogenic cancers that may respond to immunotherapy. In the study, the therapeutic vaccine combined with low-dose chemotherapy primed almost 85 percent of pancreatic ductal adenocarcinomas to potentially respond to immunotherapy.
READ FULL ARTICLE From Gastro